Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease

Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease

Abstract Background Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely way and could be used to assess loss of response (LOR) to biologics. Methods This study is a retrospective outcome review in 61 patients on adalimumab...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2021-07, Vol.27 (8), p.1237-1247
Hauptverfasser: Sorrentino, Dario, Gray, James M
Format: Artikel
Sprache:eng
Schlagworte:
Adalimumab - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Chronic Disease
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Gastrointestinal Agents - therapeutic use
Humans
Inflammation - diagnosis
Inflammation - drug therapy
Infliximab - therapeutic use
Lactoferrin - metabolism
Original s - Clinical
Retrospective Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely way and could be used to assess loss of response (LOR) to biologics. Methods This study is a retrospective outcome review in 61 patients on adalimumab, infliximab, or vedolizumab managed in our center and followed for 6 to 24 months. Patients were 1) in clinical remission or 2) were experiencing possible LOR. Results For group 1, in 71% of 31 patients, FL slowly increased during the therapeutic interval (R2 = 0.769; P 
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izaa348